Several retrospective data analyses of patients with diabetes taking antipsychotics have yielded an increased risk of either development or exacerbation of this metabolic condition-up to 3 times the risk with olanzapine, 7 times the risk with clozapine, and 2 times the risk with conventional high-potency antipsychotics (1) .
Therefore, careful and regular monitoring for diabetes pre-and posttreatment continues to remain a significant part of the psychopharmacotherapy of schizophrenia. The availability of newer antipsychotics such as ziprasidone and aripiprazole may be a step forward in managing this situation. combined with an age-related further loss of cholinergic integrity also plays a prominent role (1) . Treating this complication is difficult: because of their selective dopamine receptor antagonistic effects, most typical antipsychotic drugs worsen motor symptoms of Parkinson's disease. As a consequence of a nonselective antagonism at both serotonergic and dopaminergic receptors, atypical antipsychotics such as clozapine or olanzapine are associated with fewer extrapyramidal side effects (2) . Clozapine was the first atypical antipsychotic drug to be introduced into clinical use in several European countries, in the late 1960s (3). Clozapine treatment is associated with wide side effects that include the following: blood-cell dyscrasias, benign granulocytopenia, transient granulocytosis, and a risk of agranulocytosis as high as 0.5% to 1% (4); transient fever in up to 50% of the patients; sedation; and considerable body-weight gain. The mechanisms underlying these side effects are still unknown, but recent data suggest that the metabolism of clozapine and its immunomodulatory effects may play a role. Aplastic anemia in all its features emerging during clozapine therapy has not been documented in the literature. We present a case of clozapine-induced aplastic anemia.
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Case Report
A 53-year-old man with Parkinson's disease (according to ICD-10 criteria) developed a dopamine-induced psychosis with hallucinations. Because of his persisting psychotic symptoms, he was admitted to a psychiatric hospital, and antipsychotic pharmacotherapy of 50 mg clozapine daily was started. He developed fever after 1 week, and his blood tests revealed abnormalities (neutrophil count < 500/L, platelet count 93 000/L, and reticulocyte count < 20 000/L). Clozapine therapy was discontinued and he was admitted to our clinic. According to the criteria of the International Aplastic Anemia Study Group, we diagnosed a severe form of drug-induced aplastic anemia (neutrophil count < 500/L, platelet count 89 000/L, and reticulocyte count < 20 000/L). He received blood transfusions, and we started therapy with hematopoietic growth factors (r-metHuG-CSF) (5) and
antibiotics. The Parkinson's disease was treated with dopamine and apomorphine. After 14 days, he was responding to the therapy, and the aplastic anemia disappeared. The psychosis with delusions and hallucinations was still evident, and we established a neuroleptic therapy with quetiapine. The therapy with hematopoietic growth factors was discontinued.
We hypothesize that clozapine induced the severe aplastic anemia. The major classes of myelotoxic drugs are known, but the mechanisms by which certain agents cause aplastic anemia are still unclear. We suggest cautious use of clozapine in patients with Parkison's disease.
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Early-Onset Obsessive-Compulsive Disorder
Dear Editor:
Studies have reported high prevalence rates (6-month prevalence of 0.5% to 1%) of obsessive-compulsive disorder (OCD) in children and adolescents (1) . Although the childhood onset-age of OCD in most clinical samples has ranged from age 6 to 11 years (2), the disorder has been found in children as young as age 3 years. We report the case of patient The Canadian Journal of Psychiatry
